Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: Role of hepatitis C and B infections

Hepatology

Volumn 35, Issue 1, 2002, Pages 182-189

  Sulkowski, Mark S ^a   Thomas, David L ^a,b   Mehta, Shruti H ^b   Chaisson, Richard E ^a   Moore, Richard D ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIRETROVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; EFAVIRENZ; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ANTIMICROBIAL THERAPY; ARTICLE; DISEASE SEVERITY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR;

EID: 0036139688     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2002.30319     Document Type: Article

References (52)

1. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
2. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection
3. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection
4. Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy
5. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy
6. Severe hepatic cytolysis: Incidence and risk factors in patients treated by antiretroviral combinations. Aquitaine Cohort, France, 1996-1998
7. Reciprocal interactions between human immunodeficiency virus and hepatitis C virus infections
8. Hepatitis C virus infection as an opportunistic disease in persons infected with human immunodeficiency virus
9. Chronic hepatitis B in asymptomatic homosexual men with antibody to the human immunodeficiency virus
10. Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: An immune restoration disease?
11. Severe hepatitis in three AIDS patients treated with indinavir
12. Hepatotoxicity after introduction of highly active antiretroviral therapy
13. Comparison of initial combination antiretroviral therapy with a single protease inhibitor, ritonavir and saquinavir, or efavirenz
14. The emerging roles of non-nucleoside reverse transcriptase inhibitors in antiretroviral therapy
15. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults
16. Efavirenz as a substitute for protease inhibitors in HIV-1-infected patients with undetectable plasma viral load on HAART: A median follow-up of 64 weeks
17. Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection
18. Adverse effects associated with use of nevirapine in HIV postexposure prophylaxis for 2 health care workers
19. Adverse effects associated with use of nevirapine in HIV postexposure prophylaxis for 2 health care workers
20. Severe hepatic failure related to nevirapine treatment
21. Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection
22. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: The INCAS Trial
23. Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double- blind, placebo-controlled trial
24. Jaundice and hepatocellular damage associated with nevirapine therapy
25. Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis
26. Analysis of four key trials to assess the risk of hepatotoxicity with nevirapine: Correlation with CD4 levels, hepatitis B and C seropositivity and baseline liver function tests
27. Efavirenz-induced acute eosinophilic hepatitis
28. Therapeutic drug monitoring of nelfinavir in a prospective study in HIV-HCV coinfected patients with chronic liver disease
29. Incidence of hepatotoxicity and mortality in 21 adult antiretroviral treatment trials
30. Value of epidemiologic studies in determining the true incidence of adverse events. The nonsteroidal anti-inflammatory drug story
31. Racial differences in the use of drug therapy for HIV disease in an urban community
32. Pharmacokinetics of efavirenz in subjects with chronic liver disease
33. Sex differences in nevirapine rash
34. Female sex and the use of anti-allergic agents increase the risk of developing cutaneous rash associated with nevirapine therapy
35. Severe liver toxicity in patients receiving two nucleoside analogues and a non-nucleoside reverse transcriptase inhibitor
36. Gender specific differences related to nevirapine treatment in HIV-1 infected drug users
37. The tolerability of efavirenz after nevirapine-related adverse events
38. Therapy with efavirenz plus indinavir in patients with extensive prior nucleoside reverse-transcriptase inhibitor experience: A randomized, double-blind, placebo-controlled trial
39. Hepatotoxicity associated with non-nucleoside reverse transcriptase inhibitors for the treatment of human immunodeficiency virus and the effect of hepatitis B or C virus infection
40. Increase in hepatitis C virus load in hemophiliacs during treatment with highly active antiretroviral therapy
41. Impact of treatment with human immunodeficiency virus (HIV) protease inhibitors on hepatitis C viremia in patients coinfected with HIV
42. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients
43. Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection
44. Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors
45. Efavircnz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients
46. High plasma levels of nelfinavir and efavirenz in two HIV-positive patients with hepatic disease
47. Single-dose pharmacokinetics of amprenavir, a human immunodeficiency virus type 1 protease inhibitor, in subjects with normal or impaired hepatic function
48. Fatal portal hypertension, liver failure, and mitochondrial dysfunction after HIV-1 nucleoside analogue-induced hepatitis and lactic acidaemia
49. Liver failure after long-term nucleoside antiretrovital therapy
50. The natural history of hepatitis C virus infection: Host, viral, and environmental factors